• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Hepatic Steatosis in Insulin Resistance and Metabolic Health.

作者信息

Bae Ji Cheol

机构信息

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

出版信息

Endocrinol Metab (Seoul). 2025 Apr;40(2):304-306. doi: 10.3803/EnM.2025.2340. Epub 2025 Mar 24.

DOI:10.3803/EnM.2025.2340
PMID:40123045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12061749/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9547/12061749/0e15a4fd33b6/enm-2025-2340f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9547/12061749/0e15a4fd33b6/enm-2025-2340f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9547/12061749/0e15a4fd33b6/enm-2025-2340f1.jpg

相似文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Hepatic Steatosis in Insulin Resistance and Metabolic Health.代谢功能障碍相关脂肪性肝病：肝脂肪变性在胰岛素抵抗和代谢健康中的作用。
Endocrinol Metab (Seoul). 2025 Apr;40(2):304-306. doi: 10.3803/EnM.2025.2340. Epub 2025 Mar 24.
2
Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.胰岛素抵抗和中心性肥胖决定肝脂肪变性，并解释脂肪性肝病患者的心血管风险。
Front Endocrinol (Lausanne). 2023 Sep 29;14:1244405. doi: 10.3389/fendo.2023.1244405. eCollection 2023.
3
Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.超重和肥胖代谢功能障碍相关脂肪性肝病患者极低卡路里生酮饮食 8 周前后肝脂肪变性和纤维化的性别差异。
Nutrients. 2024 May 8;16(10):1408. doi: 10.3390/nu16101408.
4
Predicting hepatic steatosis degree in metabolic dysfunction-associated steatotic liver disease using obesity and lipid-related indices.利用肥胖和脂质相关指标预测代谢功能障碍相关脂肪性肝病的肝脂肪变性程度
Sci Rep. 2025 Mar 12;15(1):8612. doi: 10.1038/s41598-024-73132-1.
5
Menopause and metabolic dysfunction-associated steatotic liver disease.绝经与代谢功能紊乱相关的脂肪性肝病。
Maturitas. 2024 Aug;186:108024. doi: 10.1016/j.maturitas.2024.108024. Epub 2024 May 14.
6
Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.慢性肾脏病发生时代谢功能障碍相关脂肪/脂肪变性肝病的严重程度和缓解情况。
J Am Heart Assoc. 2024 Mar 5;13(5):e032604. doi: 10.1161/JAHA.123.032604. Epub 2024 Feb 23.
7
Attenuation imaging: Diagnostic differences in hepatic steatosis for chronic hepatitis B metabolic dysfunction-associated steatotic liver disease patients.衰减成像：慢性乙型肝炎代谢功能障碍相关脂肪性肝病患者肝脂肪变性的诊断差异
World J Gastroenterol. 2025 Mar 21;31(11):102795. doi: 10.3748/wjg.v31.i11.102795.
8
A Very Low-Carbohydrate Program in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease and Phospholipase Domain-Containing Protein 3 Risk Genotype: Pre-Post Intervention Study.针对患有代谢功能障碍相关脂肪性肝病且携带含磷脂酶结构域蛋白3风险基因型的成年人的极低碳水化合物计划：干预前后研究。
JMIR Form Res. 2025 Jan 10;9:e60051. doi: 10.2196/60051.
9
The predictive value of triglyceride-glucose-high density lipoprotein-body mass index (TGH-BMI) for different degrees of hepatic steatosis and liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).甘油三酯-葡萄糖-高密度脂蛋白-体重指数（TGH-BMI）对代谢功能障碍相关脂肪性肝病（MASLD）不同程度肝脂肪变性和肝纤维化的预测价值
Clin Nutr ESPEN. 2025 Apr;66:290-301. doi: 10.1016/j.clnesp.2025.01.041. Epub 2025 Jan 24.
10
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.泛过氧化物酶体增殖物激活受体激动剂拉尼非诺能改善2型糖尿病和代谢相关脂肪性肝病患者的胰岛素抵抗和肝脂肪变性。
J Hepatol. 2025 Jun;82(6):979-991. doi: 10.1016/j.jhep.2024.12.045. Epub 2025 Jan 15.

引用本文的文献

1
Global prevalence of insulin resistance in the adult population: a systematic review and meta-analysis.全球成年人群胰岛素抵抗的患病率：一项系统评价与荟萃分析。
Front Endocrinol (Lausanne). 2025 Aug 22;16:1646258. doi: 10.3389/fendo.2025.1646258. eCollection 2025.

本文引用的文献

1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
2
Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study.脂肪变性严重程度与新发糖尿病风险增加相关：一项回顾性纵向研究。
Endocrinol Metab (Seoul). 2023 Aug;38(4):418-425. doi: 10.3803/EnM.2023.1729. Epub 2023 Jul 12.
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
4
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018.胰岛素抵抗对美国非酒精性脂肪性肝病成人肝纤维化的影响：NHANES 2017 至 2018 年。
Endocrinol Metab (Seoul). 2022 Jun;37(3):455-465. doi: 10.3803/EnM.2022.1434. Epub 2022 Jun 21.
5
Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study.非糖尿病非酒精性脂肪性肝病患者胰岛素抵抗指数变化与肝纤维化风险：康伯三星健康研究。
Endocrinol Metab (Seoul). 2021 Oct;36(5):1016-1028. doi: 10.3803/EnM.2021.1110. Epub 2021 Oct 21.
6
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.非酒精性脂肪性肝病与致死和非致死性心血管事件风险：一项更新的系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3. Epub 2021 Sep 21.
7
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.非酒精性脂肪性肝病与 2 型糖尿病之间的复杂关系——机制与治疗。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612. doi: 10.1038/s41575-021-00448-y. Epub 2021 May 10.
8
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.非酒精性脂肪性肝病与新发糖尿病风险：对501022名成年人的最新荟萃分析
Gut. 2021 May;70(5):962-969. doi: 10.1136/gutjnl-2020-322572. Epub 2020 Sep 16.
9
Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.韩国非酒精性脂肪性肝病患病率的系统评价
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101526. doi: 10.1016/j.clinre.2020.06.022. Epub 2020 Sep 9.
10
The integrative biology of type 2 diabetes.2 型糖尿病的综合生物学。
Nature. 2019 Dec;576(7785):51-60. doi: 10.1038/s41586-019-1797-8. Epub 2019 Dec 4.